The following content is Conservatives aim to reduce medical costs.
Thanks to a disturbing new alliance between left-wing politicians and the nation's big pharmaceutical companies, a proposal is moving through Congress that would significantly expand the size of government and provide a taxpayer bailout of Big Pharma.
Conservatives and free-market economists are now speaking out about the disastrous effects of these policies, which undermine the free market for prescription drugs and require pharmacy benefit management to be used in negotiations with big drug companies. This would remove the incentive for PBMs to secure higher rebates. . These rebates help plan sponsors, such as small businesses, save money to reduce prescription drug costs and provide better benefits for their employees.
Big Pharma is pushing to “decouple” incentives for PBMs to negotiate lower drug prices on behalf of employers and patients. $32 billion windfall It is expected to be accepted in the commercial and Medicare Part D markets.
Republicans prefer Rep. Eric Burleson (R-Missouri) recognize He argued that these proposals would “only increase prescription costs for patients” and put America on the path to a socialist health care system.Congressman Burlison predicted:
I think we're on the path to a single-payer solution, and if Congress wants that, that's what we're going to get, it's going to mean people's health care costs, health insurance premiums going up. It will…Every time Congress does something related to health care, all it has done is reduce patient access and choice, increase costs, and reduce quality. . So we can mandate it all day long, but if the market can't provide it, it won't happen.i really believe that [Congress] It really disrupts the healthcare system. This is no longer a free market, it's the last bastion of choice in health care…The most innovative thing in the last few years has been pharmacy benefit managers, and they're actually reducing the cost of bargaining all together. is completed. . For us to kind of knee-jerk with that program…it's beneficial for the drug companies, but it's not beneficial for the insurance payers.
Economic experts recognize that strong competition is the very foundation of the free market system that the left wants to slowly dismantle. As Joel Zinberg of Competitive Enterprise Institute (CEI) explainPBMs “promote competition through group purchasing and negotiated discounts” to ensure that patients and taxpayers pay less for prescription drugs.
PBM is the procompetitive creation of prescription drug markets that improves consumer welfare. They reduce costs for drug insurance plan sponsors and their patient customers through group purchasing and negotiating different contract terms, leading to lower drug prices, increased drug utilization, and improved health outcomes. The fact that PBMs thrive in the free market confirms that they add value to participants in the prescription drug distribution system.
Understandably, Big Pharma loathes other actors in the drug supply chain who loosen their monopolistic grip on setting exorbitant drug prices to rip off patients, employers, and taxpayers. As Alex Brill, a conservative health economist and founder and CEO of Matrix Global Advisors (MGA), points out in a recent book: panel discussionThe move to undermine the competitiveness of the prescription drug market is the latest attempt by Big Pharma to “blame” PBMs to distract itself.
From a manufacturer's perspective, I think there is an opportunity to limit the flexibility of PBMs to their own benefit, the manufacturer's benefit. So it's the politics of changing the conversation. Even if nothing happens, at least they've moved the conversation away from themselves. If something were to happen, they could be the beneficiary… If PBMs are stripped of their tools and incentives, they may not be able to drive prices down as much in the future as they have in the past. So here too there will be winners and losers. Therefore, the winners will likely be drug manufacturers, and the losers will likely be employers who receive higher premiums.
Ike Brannon, another conservative economist, is a senior fellow at the institute. jack kemp foundationhave asked a question Why would a politician who claims to support the free market create a policy that would put more government into the prescription drug market to the detriment of taxpayers?
Plan sponsors can choose how they will be compensated and contracted with the PBM. As healthcare costs continue to rise, limiting the ability to contract with a PBMS will increase drug costs. It is unclear why politicians who generally advocate free market policies feel compelled to pursue policies that restrict the prescription drug market without beneficial outcomes for taxpayers…Pharmacy benefit managers It is one of the few mechanisms we have to suppress this. You should think carefully before taking steps to limit them.
Meanwhile, local community leaders like Richard Kaxdorf of Bonduel, Wis. recognize Policy “decoupling'' will have a negative impact on small businesses and their employees across the country.
We need to do something to lower drug prices and health care costs, but this type of policy is counterproductive. I hope Wisconsin legislators look at the data, talk to small business owners, and realize that “unlinking” is the wrong approach to lowering prescription drug costs.
As free markets come under attack from Big Pharma and the left, conservatives are left to defend perhaps the last remaining “bulwark” (in Burleson's words) in the health care system. It's the pharmacy benefits market. Without resistance from powerful conservatives on the floor of Congress, the government's efforts to take full control of the nation's health care system are likely to succeed, resulting in billions of dollars in new profits for Big Pharma. can be obtained.
For more information, see Conservative for Low Health Care Costs.
